Real-time, label-free monitoring of living cells is a central goal in biosensing, and mid-infrared spectroscopy is uniquely suited to this task because it directly probes the vibrational fingerprints of biomolecules within cells. However, its use in live-cell analysis is limited by weak absorption signals and strong water background. Here, we introduce a double-resonant plasmonic metasurface composed of gold rod-shaped nanoantennas specifically engineered to overcome these limitations. This metasurface provides two complementary spectral readouts: (i) a strong plasmonic resonance matched to the amide I-II vibrational bands of proteins, and (ii) a sharp reflectance dip around 1900 cm-1 optimized for refractive-index mass sensing via plasmonic redshift. Initial validation with red blood cell sedimentation showed sensitivity to time-dependent refractive index variations corresponding to ∼3.5 ng of deposited material. We then applied this technology to a clinically relevant model, monitoring SAS oral squamous carcinoma cells treated with 18β-glycyrrhetinic acid, a natural compound with pro-apoptotic effects. Treatment resulted in a clear decrease in both the plasmonic redshift signal and the integrated amide absorption, consistent with biophysical and biochemical alterations associated with apoptosis. Spectral deconvolution of the amide I region revealed specific shifts in protein secondary structures, including a decrease in α-helical content, further supporting apoptosis-related molecular changes. These findings show that our plasmonic metasurface can sensitively monitor real-time cellular responses, supporting applications in drug screening, spectral biomarker discovery, and opening new opportunities in cell-based diagnostics and biosensing.
Niccolini, B., Di Santo, R., Mazzinelli, E., Orlando, M., Russo, A., Ortolani, M., Di Gaspare, A., Rosa, E., Notargiacomo, A., Pea, M., Saini, N., De Spirito, M., Baldi, A., Setayeshmehr, K., Guidi, F., Nocca, G., Ciasca, G., Dual-mode mid-infrared plasmonic metasurface for real-time label-free analysis of live cells, <<TALANTA>>, 2026; 2026 (301): 129240-129250. [doi:https://doi.org/10.1016/j.talanta.2025.129240] [https://hdl.handle.net/10807/338230]
Dual-mode mid-infrared plasmonic metasurface for real-time label-free analysis of live cells
Niccolini, BenedettaPrimo
;Mazzinelli, Elena;Russo, Alessandra;De Spirito, Marco;Nocca, GiuseppinaPenultimo
;Ciasca, GabrieleUltimo
2026
Abstract
Real-time, label-free monitoring of living cells is a central goal in biosensing, and mid-infrared spectroscopy is uniquely suited to this task because it directly probes the vibrational fingerprints of biomolecules within cells. However, its use in live-cell analysis is limited by weak absorption signals and strong water background. Here, we introduce a double-resonant plasmonic metasurface composed of gold rod-shaped nanoantennas specifically engineered to overcome these limitations. This metasurface provides two complementary spectral readouts: (i) a strong plasmonic resonance matched to the amide I-II vibrational bands of proteins, and (ii) a sharp reflectance dip around 1900 cm-1 optimized for refractive-index mass sensing via plasmonic redshift. Initial validation with red blood cell sedimentation showed sensitivity to time-dependent refractive index variations corresponding to ∼3.5 ng of deposited material. We then applied this technology to a clinically relevant model, monitoring SAS oral squamous carcinoma cells treated with 18β-glycyrrhetinic acid, a natural compound with pro-apoptotic effects. Treatment resulted in a clear decrease in both the plasmonic redshift signal and the integrated amide absorption, consistent with biophysical and biochemical alterations associated with apoptosis. Spectral deconvolution of the amide I region revealed specific shifts in protein secondary structures, including a decrease in α-helical content, further supporting apoptosis-related molecular changes. These findings show that our plasmonic metasurface can sensitively monitor real-time cellular responses, supporting applications in drug screening, spectral biomarker discovery, and opening new opportunities in cell-based diagnostics and biosensing.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



